chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Treatment of COVID-19/ Antigen test was more positive (bright red line) than any previous day; Treatment of COVID-19/ Antigen test was more positive (bright red line) than any previous day; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 27-year-old male patient received BNT162b2 (BNT162B2), in Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) and in Jun2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 27 years for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (COVID-19 VACCINE MODERNA), in Feb2021 as dose 1, single (Batch/Lot number: unknown) and in Mar2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing), notes: Other medical history: asthma; "Known allergies: Penicillin" (unspecified if ongoing), notes: Known allergies: Penicillin; "Known allergies: kiwi" (unspecified if ongoing), notes: Known allergies: kiwi. Concomitant medication(s) included: ALBUTEROL HFA. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19/ Antigen test was more positive (bright red line) than any previous day". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Unknown results; (17Jul2022) Negative, notes: Antigen test was negative days 6-7 and continued no symptoms; (18Jul2022) Negative, notes: Antigen test was negative days 6-7 and continued no symptoms; (19Jul2022) Positive, notes: On day 8, I woke up with a sore throat, fever, and nasal congestion. Antigen test was more positive (bright red line) than any previous day. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical Information: It was reported that, other medication in 2 weeks reported as Albuterol inhaler. Patient started Paxlovid on day 2 of symptoms. Symptoms resolved and antigen test had a faint line by day 4. Antigen test was negative days 6-7 and continued no symptoms. On day 8, patient woke up with a sore throat, fever, and nasal congestion. Antigen test was more positive (bright red line) than any previous day. Anti-viral details of product for COVID 19 reported as, treatment started on 12Jul2022, and treatment stopped on 17Jul2022 for COVID-19.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
HIVES OVER MUCH OF THE BODY, BEGINNING AS SMALL RED SPOTS & GROWING TO LARGE RED AREAS OVER THE COURSE OF SEVERAL WEEKS. SOME ITCHING & FLAKING.
Prolonged soreness in right arm lasting from vaccination on 11/10/2016 through the date he reported it on 01/18/2017.
Patient was found down.  Intubated upon arrival to ER.  Head CT showed intraventricular hemorrhage.  EVD placed emergently.  Cerebral Angiogram  did not show a large vessel source.  Subsequent Head CTs are stable but the patient is not recovering.  Neuro is not improved.  Family is planning to possibly terminally withdrawal this week.
Shingles 4 years after 2 doses of Shingrix/suspected vaccination failure; Developed symptoms of Shingles; This case was reported by a consumer and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included Herpes zoster (Shingrix) for prophylaxis.   In May 2018, the patient received the 2nd dose of Shingrix. In March 2018, the patient received the 1st dose of Shingrix. On an unknown date, 4 years after receiving Shingrix and Shingrix, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingrix and Shingrix.     Additional Information: GSK Receipt Date: 06-MAY-2022 Reporters comment: The patient self-reported the case. The patient developed symptoms of Shingles 4 years after receiving Shingrix.  The patient asked if it was possible to get a second round of the vaccine.  Pharmacist said no, but he would not ask GlaxoSmithKline representative. Additional supportive information: This case was considered as suspected vaccination failure, since the details regarding laboratory test confirming shingles was unknown at the time of reporting.
fever, blisters, pain,  tingling on Rt side  frank, back, thigh, back
Patient was given a undiluted Pfizer COVID 19 vaccine.  Patient received 2.8 ml of undiluted vaccine.
This spontaneous report as received from a physician via company representative refers to an unspecified number of patients (also reported as: "3 out of every 10 patients) of unknown age and gender. Concomitant medication, pertinent medical history, drug reactions or allergies were not provided. On an unknown date, unspecified number of patients were vaccinated with GARDASIL 9 (dose, route of administration, lot #, expiration date - not reported). On an unknown date, the patients experienced injection site pain followed by fainting when received GARDASIL 9. The adverse events occurred while the patients were in the office. The outcome of events was unknown. The relatedness between the event and GARDAISL 9 was not reported. No other details were provided. Additional information has been requested.
This is pediatric pfizer. Patient was fine, very confident, talking. I left room in about 5 minutes. Mom called me back he went limp, couldn't move, fainted. We kept talking to him. Tech got him water and called 911. Squad came in about 10 minutes. Before squad came he was fine again as if nothing happened. EMTs checked bp, vital signs, etc.
Pain; Swelling; flu-like symptom; This case was reported by a physician via sales rep and described the occurrence of pain in a patient who received Men B NVS (Bexsero) for prophylaxis.   On an unknown date, the patient received the 1st dose of Bexsero. On an unknown date, unknown after receiving Bexsero, the patient experienced pain, swelling and influenza-like symptoms. On an unknown date, the outcome of the pain, swelling and influenza-like symptoms were not reported.   It was unknown if the reporter considered the pain, swelling and influenza-like symptoms to be related to Bexsero.  Additional details were provided as follows: The age at vaccination was not reported. After receiving the Bexsero, the patient experienced pain, swelling and flu-like symptoms. The reporter consented to follow up from GSK.
PATIENT RECIEVED PFIZER VACC. AS SECOND DOSE SHE WAS A TRANSFER FROM A DIFFERENT FACILITY AND HAD RECIMVED MODERNA ON FIRST DOSE ; DID NOT PROVIDE THAT INFORMATION PRIOR TO VACCINATION I DISCOVERED IT AFTER THE PHFIZER HAD BEEN ADMINISTERD. NO ADVERSE EVENTS HAVE BEEN REPORTED
On January 24, 8 days after receiving the first dose of the Moderna vaccine, my knuckles and toes started to feel itchy. On the 9th day, red bumps started appearing on both my hands and toes, mainly in the knuckles and joints. A rash also appeared on the arm (left arm) where my vaccine was administered. By the 10th day, my hands, left arm, elbows and toes were covered with red, itchy bumps. My primary physician determined this was an allergic reaction to the Moderna vaccine and prescribed fexofenadine and triamcinolone acetonide ointment. As of January 29th, 13 days after the first dose, the redness and the bumps in my left arm, hands and toes have reduced, but the itchiness is still present in all areas except my left arm.
Flu symptoms including fever of 101, chills, body aches, head pressure, and fatigue. These symptoms started in the early morning the day after I got the vaccine. The fever and chills were gone the same day in the afternoon and the body aches, head pressure, and fatigue were gone by the following morning. I also had soreness at the injection site and hives on my neck and upper chest for several days.
Right side total facial paralysis Hospital ER -  March 19, 2021 Dr  Vision - March 19, 2021, April 04, 2021, April 16, 2021,  April 29, 2021 Dr  - PCP - March 31, 2021, April 07, 2021, April 14, 2021, May 25, 2021, July 21, 2021 Dr  ENT - April 21, 2021, May 12, 2021 Dr  ENT - May 07, 2021 (future appointment August 24, 2021) Dr  Ocular Prosthetics- June 24, 2021  Prednisone / Valacyclovir Hel 1 Gram Tablet / Lacrilube
had measles vaccine on 9/13/07 ad on 9/24/07 developed measles-like rash head to toe.
41yr old patient previously received COVID-19 J&J (Janssen) Vaccine on 3/12/21 (LOT # 1802070).  After reading about increase of breakthrough cases after 8months, patient scheduled COVID-19 Moderna vaccine appointment.  On 8/20/21, LPN administered COVID-19 Moderna vaccine (LOT # 007C21A) to patient's left deltoid.  Order for Moderna SARS-CoV-2 (COVID-19) Vaccine authorized by NP.  Patient returned to clinic on 10/8/21 for second dose of Moderna vaccine.  Of note, COVID-19 Janssen vaccine is a one dose series and the patient would not need another COVID 19 vaccine series.  Error was identified prior to second Moderna vaccine administration.  Patient informed that COVID leadership would be contacted to clarify if patient should continue Moderna series.  No patient harm noted.  Decision not to administer second dose of Moderna series until more guidance from FDA/CDC regarding interchangability of vaccines.
This case was reported by a physician via call center representative and described the occurrence of pertussis in a female patient who received KINRIX (batch number EP2A3, expiry date unknown). On 22nd October 2014, the patient received KINRIX. On an unknown date, 1 year after receiving KINRIX, the patient experienced pertussis (serious criteria GSK medically significant) and infection. The patient was treated with BACTRIM. On an unknown date, the outcome of the pertussis and infection were unknown. It was unknown if the reporter considered the pertussis and infection to be related to KINRIX. Additional details were provided as follows: The patient received KINRIX last year on 22nd October 2014. According to the reporter, at the time of reporting, approximately 1 year after vaccination when the patient was 6 years of age, the patient was diagnosed with pertussis. The pertussis culture was negative for this patient but 3 out of 6 house-hold family members had positive pertussis culture. He thought that this patient's pertussis culture came out negative because the patient was taking BACTRIM for an infection (not related to suspected pertussis).
This case was reported by a physician via a sales representative and described the occurrence of possible cellulitis in a 27-year-old female subject who was vaccinated with TWINRIX (GlaxoSmithKline). Previous vaccination included 1st dose of TWINRIX (GlaxoSmithKline) given on an unspecified date. There were no concurrent medications. On the afternoon of 18 April 2011 the subject received a 2nd dose of TWINRIX at 1.0 ml in the left arm. On 18 April 2011, less than one day after vaccination with TWINRIX, the subject experienced injection site pain, injection site soreness, injection site warmth and swelling at the injection site. It was reported that the subject's arm was swollen. It was reported that the symptoms got worse overnight. The subject experienced difficulty moving her arm and the events were "limiting" her (activities of daily living impaired) but not considered to necessarily be "disabling." The subject went to see her physician and the physician suspected possible cellulitis or joint infections. He was planning to have the subject follow-up in two days. This case was assessed as medically serious by GSK. At the time of reporting the events were worse. It was noted that the subject did not have any reaction from the 1st dose of TWINRIX.
i took your Pfizer vaccine both of them and you know that I got COVID; i took your Pfizer vaccine both of them and you know that I got COVID; chills; the features of my face and skin changed; tongue felt, tasted bitter; lost a lot of weight; lost your appetite; This is a spontaneous report from Pfizer. A contactable consumer (patient) reported that a 74-year-old patient of an unspecified gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE lot/batch number and expiration date not reported) via an unspecified route of administration on an unspecified date as 1st dose, single and as 2nd dose, single for COVID-19 immunisation; estrogens conjugated, medroxyprogesterone acetate (PREMPRO), via an unspecified route of administration from an unspecified date, at 2.5 mg for an unspecified indication; estrogens conjugated (PREMARIN), via an unspecified route of administration from an unspecified date at an unspecified dose and frequency for an unspecified indication; and celecoxib (CELEBREX), via an unspecified route of administration from an unspecified date at an unspecified dose and frequency for an unspecified indication. The patient's medical history and concomitant medications were not reported. The patient took the Pfizer vaccine both of them and the patient got COVID and was better. "I only got it for two days, this is three months ago and I got it from my husband but the side effects after the aftermath lingers on and it effects other things in my body. I got the chills for two days and the features of my face and skin changed with COVID and I got the chills for two days and then your tongue felt, tasted bitter. I lost a lot of weight because you lost your appetite." The action taken in response to the events for estrogens conjugated, medroxyprogesterone acetate, estrogens conjugated and celecoxib was unknown. Outcome of the event i took your Pfizer vaccine both of them and you know that I got COVID was recovered on an unspecified date while unknown for the other events.   Information on the lot/batch number has been requested.
tc from mom who stated rt leg red & swollen & wont bend leg; states applying cool compresses but still wont bend leg; states inc temp yesterday but none today;
major-motor generalized sz lasting 10 minutes; occurred w/in 1 hr of vax;
Aching arm, stomach pain, vasovagal (fainting) event occurred twice on Saturday 11/20.
Musical ear syndrome (MES), songs followed by old fashioned roller rink organ music which has devolved into only the organ music repeating 4-5 lines over and over. This hasn't stopped,goes 24 hours a day, and interrupts my sleep. It is usually low and in the background. I e been told there is no treatment or cure but that hearing aids might possibly drown it out. Musical Ear Syndrome (MES), in which there are many members who also say they got this as a side effect of a covid vaccination.
Site of injection was red, raised and warm when bandaid was removed 2 hrs after injection. Slightly itchy just after injection. Symptoms worsened over the next 24 hrs. Red area grew in size and continued to be raised, warm to touch and firm. Itchy increased substantially after 48 hrs.
9:16 Blood pressure 180/82 Throat pain and funny feeling 9:20 Offered epi pen and wanted to wait 9:23 Epi given in left thigh and EMS contacted  9:27 142/77  9:33 EMS arrival
Atrial fibrillation, required electrical cardio version. Heart rate topped at apex 180 BPM
Systemic: Fainting / Unresponsive-Mild, Additional Details: Patient fainted 5 to 6 minutes after vaccination
Dose given more than 12 hour post-puncture; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose given more than 12 hour post-puncture) in a 51-year-old female patient who received mRNA-1273 (Spikevax) (batch nos. 033K21-2A and 068H21A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Feb-2022, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 11-Mar-2022, received second dose of mRNA-1273 (Spikevax) (unknown route) dosage was changed to 1 dosage form. On 11-Mar-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose given more than 12 hour post-puncture). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose given more than 12 hour post-puncture) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided.   It was reported that the vaccine was punctured on thursday morning 10-Mar-2022 at 9:24 AM. Date the vial was initially stored in the refrigerator was 10-Mar-2022 and the vial did not undergo any temperature excursions. Amount of time the vial was exposed to room temperature range (8° to 25°C= 46° to 77°F) was very minimal (only taken out to draw the doses).  No treatment medication were provided.
Swelling in the left axilla region, tender to touch.  Started approximately 24 hours after 2nd injection, ongoing at the time of this report.
Unsure if related, but menstrual period is over 7 days late. Multiple negative pregnancy tests confirming not due to pregnancy.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) in a 43-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 15-Apr-2021 at 4:26 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 15-Apr-2021 at 4:26 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant product use was reported.  The age of patient was provided as 43.97.  It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  On 15-Apr-2021, the excursion time on initial supply was 09 am, temperature was 34. Total 188 doses were administered for that day, condition of vaccine prior to vaccination was not frozen. Vaccine moved to fridge on 06-Apr-2021 and moved to clinic on 15-Apr-2021. 18 vials were moved to the clinic. Vaccine BUD date was 09-May-2021.  On 15-Apr-2021, vials were stored in cooler 1, at following time and temperature respectively, 9 AM: 34, 10 AM: 36, 11 AM: 38, 12 AM: 39, 1PM: 43, 2 PM: 44, 3 PM: 44, 4 PM: 42 and 5 PM: 42.  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic. The temperature recordings were taken by using a Fisher brand traceable temperature monitor at every hour. After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  No treatment information was provided.
IM influenza vaccine was mistaken for "Flu Mist" and administered to the nasal passage as a liquid. Once mistake was determined it was given IM
Quite miserable; A spontaneous report was received from a consumer concerning for a female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and felt quite miserable.   The patient's medical history was not provided. Concomitant product use was not provided by the reporter.    On 29 Dec 2020, the patient received her first of two planned doses of mRNA-1273 (Batch # 026L20A) intramuscularly in her left deltoid for prophylaxis of COVID-19 infection.   On 30 Dec 2020, the patient felt quite miserable. No treatment information was provided.  Action taken with mRNA-1273 in response to the event was not provided.  The outcome for the event quite miserable was unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
pt recv vax 2AUG98 & 4AUG98 exp transverse myelitis & was hosp for 6 days;pt recovered & was discharged;
CC:  Severe Swelling following vaccination. History:  Patient reports about 2 ½ days ago patient presented to the Immunization clinic for vaccination.  She was given the Tetanus/Pertussis vaccine.  She reports within a couple hours she noticed a lot of pain in the arm.  She reports the arm was uncomfortable when trying to sleep.  The following morning the lump was a lot bigger.  No numbness or tingling in hands.  She reports using warm compresses and the took Motrin.  The first day it started out being a small painful area but by the second day it covered her whole Deltoid area.  She complains of problems working out due to the pain.  She was able to sleep but it was mildly uncomfortable.  No numbness or tingling.  She complains of feeling warm but did not take her temperature.  No chills.  She reports two bouts of water like stools last night but no blood.  Today she awoke with continued swelling and tenderness and she was concerned that she might have an Abscess.  No hives or shortness of breath. O: PHYSICAL EXAM: VITALS:  Temperture 97.2 degrees   GEN:  WD, WN in NAD, appears stated age  Psy:  Interaction normal for age;  orientation, mood and affect appear normal Chest:   Normal respiratory effort without accessory muscle use; good air movement, CTA bilaterally CV:  RRR, nl S1 S2; no murmur heard  Skin: 7X7 cm induration with 12X10 erythema of the skin over the right Deltoid.  No sharp erythematous border no weeping or oozing
itching at injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PRURITUS (itching at injection site) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PRURITUS (itching at injection site). At the time of the report, VACCINATION SITE PRURITUS (itching at injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication information was provided.  No treatment medication information was given.
The patient complained on 7/30/19 that she had a sore arm with some swelling the day after receiving the Shingrix. She stated the the swelling went away within a couple of days but arm pain and restricted range of motion continued till the present day. She stated that her physician said she has tendinitis from the Shringrix vaccine and she is seeking physical therapy.